The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Once again, Dupixent finished in second place with an impressions SOV of 5.40% and 2.8 billion impressions. Notably, the ...

“After working with my dermatologist, she recommended I start Dupixent, a treatment for people ages 6 months and older with uncontrolled moderate-to-severe eczema.” Dupixent, known clinically ...

Dementia treatment is more than just medication. It can include lifestyle changes, multimodal therapy, and environmental management, as well. Your dementia treatment plan will depend on underlying ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

Another, EVO301, could reach Phase 2 testing in a common type of eczema in 2025 as well ... Many of the experimental drugs in testing, among them Celldex’s barzovolimab and Sanofi and Regeneron’s ...